On the other hand, the association of Tim-3 gene expression with clinical outcomes appeared dependent on the tumour type: specifically, higher levels of Tim-3 expression in lung and ovarian cancers correlated with improved patient prognosis, while it was associated with less favourable overall survival in patients with gastric cancer. This evidence concerns the gene HAVCR2 and ovarian carcinoma.